The StemCyte International Cord Blood Center in Arcadia, CA has achieved an enviable record in successful transplant engraftment. StemCyte cord blood units have been used in the U.S., Brazil, Taiwan, Hong Kong, Singapore, Malaysia, Israel, Australia, Spain, and elsewhere. Many of these stem cell units result in white blood cell engraftment within twenty days. Importantly, even patients as large as 220 pounds (100 kg) have been transplanted successfully.

• Outstanding engraftment rate for unrelated, children and adult and multi-unit cases.

• World’s first successful multi-cord (two cord blood units used together) non-myeloablative cord blood transplant performed by Professor Patrick Tan of Singapore General Hospital was provided by StemCyte International Cord Blood Center.

• The outstanding transplant engraftment rate and kinetics are due to our Stem Cell Optimization Process that results in outstanding post-processing cell dosage and post-thaw viability.

• StemCyte cord blood stem cell products have been used by leading transplant centers around the world. The list includes: Fred Hutchinson, Harvard University/Dana Farber, Harvard University/Massachusetts General Hospital, Columbia, UCLA, UCSF, Singapore General, National Taiwan University, Children’s Hospital of Philadelphia, and University of Michigan among others.

• StemCyte, Inc. operates one of the most racially diverse cord blood banks in the world. The size of the StemCyte cord blood stem cell bank has resulted in 50% to 90% HLA-typed match rates for patients of Asian, Hispanic, Caucasian and African American descent at four out of six or better matches.

• The StemCyte International Cord Blood Center is managed by a medical and laboratory team unequaled in the industry. There are six physicians, three Ph.D. laboratory directors, two compliance officers, and numerous technologists, technicians and nurses. The team’s expertise in cord blood banking, transfusion medicine, tissue typing, microbiology, virology, obstetric nursing, pharmacology, and cell and cancer biology is unprecedented.

• The team is led by hematologist and blood bank pioneer, Lawrence D. Petz, M.D., Chief Medical Officer and Medical Director at StemCyte. Dr. Petz is a pre-eminent authority in blood banking, and his distinguished career includes being Chairman of the Division of Medicine, Section Head of Hematology, and Director of the Department of Clinical and Experimental Immunology at the City of Hope National Medical Center. Dr. Petz also served as Director of Transfusion Medicine and Professor of Pathology & Laboratory Medicine at UCLA Medical Center.